Clinical trials: Depression
Depressive Disorder, Anxiety Disorders
AI to Support Mental Health Case Management Providers
The goal of this clinical trial is to assess the effectiveness of an artificial intelligence (AI) platform for case managers in a nonprofit health system specializing in mental health and substance use disorder.
- Conditions
- Depressive Disorder, Anxiety Disorders, Substance Use Disorders, Post Traumatic Stress Disorder
- Trial name
- NCT06280170
- Testing
- Artificial Intelligence platform for case managers
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Eleos Health
Respiratory Depression
Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users.
- Trial name
- NCT03996694
- Testing
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- BioDelivery Sciences International
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Treatment Resistant Depression
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in…
- Trial name
- NCT05598931
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soterix Medical
Depressive Disorder
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of…
- Trial name
- NCT00250653
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- Sanofi
Depressive Disorder, Major Depressive Disorder
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Depressive Episode
- Trial name
- NCT05701345
- Testing
- OMNIFIT DTx-MDD, standard treatment
- Where
- 5 sites in South Korea
- Volunteers
- 162 people
- Sponsor
- Omni C&S
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Anxiety Depression
Effectiveness and Safety of Probiotics in Relieving Anxiety and Depression
To evaluate the effectiveness and safety of probiotics in relieving anxiety and depression in adults, in comparison with placebo.
- Trial name
- NCT06629441
- Testing
- Probiotic group
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Depressed Lateral Condyle Fracture, Benign Bone Tumour Cavity
Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study
The main aim is to evaluate the long-term safety and bone healing in the operated area and to compare bioactive glass granules with autogenous bone as a filler material.
- Conditions
- Depressed Lateral Condyle Fracture, Benign Bone Tumour Cavity, Spinal Fusion
- Trial name
- NCT00935870
- Testing
- Bioactive glass and/or autogenous bone
- Where
- Finland
- Volunteers
- 63 people
- Sponsor
- Vivoxid Ltd
Depressive Disorder, Major
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
To determine if the NMDA antagonist, CP-101,606, is effective for depression
- Trial name
- NCT00163059
- Testing
- NMDA Antagonist, CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Insomnia
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00435279
- Testing
- Eszopiclone, Venlafaxine
- Where
- 69 sites in Austria, Croatia and 8 more
- Volunteers
- 678 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
- Trial name
- NCT01741142
- Testing
- ABT-436, Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 19 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Depression
A Feasibility Study of an AI-Powered Clinical Decision Aid for Personalized Depression Treatment Selection
The Clinical Decision Aid (CDA) is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of possible…
- Trial name
- NCT04061642
- Testing
- Clinical Decision Aid
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Aifred Health Inc.
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095758
- Testing
- Antidepressant + Aripiprazole
- Where
- 28 sites in United States
- Volunteers
- 1,151 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Unipolar Depression
Transcranial Direct Current Stimulation for Depression
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
- Trial name
- NCT07042217
- Testing
- transcranial direct current stimulation (tDCS) and mindfulness instruction
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical